The recent advances in understanding the specificity of genes on metabolic pathways' and the action of genes on molecular structure of protein2 provide an impetus for the study of more complex interactions of genes at the level of biochemical differentiation and quantitative regulation of enzymes. These latter features are especially apparent in mutants of higher forms of life, where the deletion of an enzymic activity may be incomplete in regard to quantity, anatomical distribution, or timing.3 I- Particularly adaptable to such inquiries 4' 6, 7 has been the hereditary condition of humans, primaquine-sensitive hemolytic anemia,8 9 a disorder characterized by an 85-95 per cent reduction in activity of glucose-6-phosphate dehydrogenase (G-6-PD*) G-6-P + TPN 6-PG + TPNH in erythrocytes,10 and by a tendency for these erythrocytes to undergo destruction when an affected individual takes primaquine or certain aromatic drugs.
Previous reports have dealt with a comparison of the lability, chromatographic behavior, and catalytic parameters of partially purified G-6-PD from normal (N) and primaquine-sensitive (S) erythrocytes.4 11 12 No significant difference was found between the G-6-PD from both sources. Those findings are here supplemented -with the studies of the erythrocytic G-6-PD from a Caucasian male infant with congenital non-spherocytic hemolytic anemia (H), a chronic, hemolytic disorder which recently has been noticed also to be associated, in some pedigrees, with an almost complete absence in activity of erythrocytic G-6-PD.13, 14 Because of the different racial stock from which such patients come and because of the more severe and chronic symptoms, it has seemed reasonable to assume that congenital nonspherocytic hemolytic anemia represents a condition distinct from primaquinesensitive hemolytic anemia. The genetic and clinical features of this particular case will be reported elsewhere.
Materials and Methods.-The G-6-PD was followed continuously, in a Beckman DU spectrophotometer, according to the method of Kornberg and Horecker,"5 as previously described. 12 The preliminary observations on hemolysates were made by using as a blank a cuvette containing the hemolysate and all components except G-6-P. Each By incorporating methods previously described,4 "l partial purification of the G-6-PD was achieved for these studies, as follows. Freshly drawn, heparinized, venous blood is centrifuged at 1,000-3,000 g for 15 min and supernatant plasma withdrawn and discarded. The top layer of white cells is teased free of the hemolysate with the tip of a micropipette. This layer is discarded. The packed erythrocytes are washed twice in five volumes of 0.15 M NaCl. After the last centrifugation the packed cells (volume = y ml) are hemolyzed by mixing with 9 y ml distilled water, and the stroma is centrifuged down at 10,000 X g for 30 min. The supernatant hemolysate is adjusted to 40 y ml and 0.02 Molar in sodium phosphate buffer, pH 6 .3. The hemolysate is then mixed with 0.8 y gin. (0.8 gm. dry weight per ml of initial packed erythrocytes) of diethyl amino ethyl cellulose (DEAE, Eastman Kodak Co.)'6 which has been equilibrated against 0.02 AMI phosphate buffer, pH 6.3. The mixture is filtered on a Buchner funnel and rapidly washed with 0.02 M phosphate buffer, pH 6.3, until the DEAE is free of hemoglobin. The enzyme is then eltited with 10 y ml of 0.5 M phosphate buffer, pH 6.3. The eluate is brought to 70 per cent saturation (4°C) with solid ammonium sulfate. Mercaptoethanol is present in a 1:2,000 dilution in all solutions. The eluate is made 0.1 per cent (w/v) in ethylene diamine tetraacetic acid (EDTA), pH 7.0. The suspension of enzyme is concentrated to between '/4 y and y ml by centrifuging and discarding supernate. To each ml suspension is added 1.12 ml distilled water to bring the mixture to 33 per cent saturation with ammonium sulfate. After centrifugation, the supernate is isolated and brought to 53 per cent saturation by the addition of 0.42 ml of saturated ammonium sulfate per ml supernate. The precipitate is stored at 40C, as a thick suspension, in the 53 per cent saturated ammonium sulfate. These steps result in a 60-80 fold purification of the G-6-PD and yield a preparation essentially free of hemoglobin and 6-PG dehydrogenase. Certain advantages in the use of this incompletely purified preparation have been cited.4 That this preparation is by no means pure is indicated by column chromatography4 and by the more recent achievement of over 10,000 fold purification of G-6-PD from normal blood.'7 Just prior to each experiment a small amount of suspension is dissolved in 0.5 ml distilled water, containing 10-5 M TPN, and dialyzed for 6 hr against three changes of a solution which is 0.02 or 0.05 M in phosphate buffer, pH 6.3, 10-5 M in TPN, and 1:1,000 in mercaptoethanol. The ionic strength of the dialysate is found to be essentially the same as unused dialyzing solution after this step. All purifications and storage are carried out at 4VC.
Results.-When a hemolysate was prepared by the addition of 9 or 19 volumes distilled water to the washed, packed erythrocytes from the infant with nonspherocytic hemolytic anemia, the activity of G-6-PD was observed to fall rapidly as the hemolysate stood at 0C. The activity immediately after hemolysis was 1.6 O.D. units (at 340 ms)/min, per ml packed cells, in an assay of 1 ml total volume and 1 cm light path (250C). This corresponds to approximately 9 per cent of normal activity. The activity was <0.1 O.D. units, or essentially imperceptible, 3 hr after hemolysis. The rapid fall in activity was observed even after stroma was removed from the hemolysate. This lability was far greater than that which was observed under comparable conditions in hemolysates from normal or primaquinesensitive humans.
Relatively small amounts of various substances stabilize or inactivate human G-6-PD; the stability also varies with the degree of dilution of the enzyme.4' 11 In order better to distinguish whether the lability was due to extrinsic or intrinsic factors, G-6-PD from this individual with non-spherocytic hemolytic anemia was purified through the step of suspension in 53 per cent saturated ammonium sulfate. The precipitate from this suspension was then diluted to approximately 2 mgm protein18/ml with 0.05 M phosphate buffer, pH 6.3, containing 10-5 M TPN. Two tenths ml was placed in each of two Pyrex centrifuge tubes (A and B) . G-6-PD from a normal adult control was purified, as here described, to the step of suspension in 70 per cent ammonium sulfate. The suspension of G-6-PD (N) was then diluted tenfold in additional 70 per cent saturated ammonium sulfate and was centrifuged; 20 Al of supernate, containing no activity, was added to tube A, as a control. The G-6-PD (N) in this 70 per cent saturated ammonium sulfate was then resuspended and 20 ,Al, or approximately 3.5 y protein, was added to tube B in order approximately to double the activity in B. Both tubes were incubated in a water bath at 49°C. The loss in activity on heating (Table 1) suggests, but by no means proves, that the erythrocytic G-6-PD (H) is intrinsically more labile than that from normal controls.
Low concentrations of TPN, which stabilize the G-6-PD from normal and primaquine-sensitive persons," do not impart normal stability to G-6-PD (H) ( Table 1) . However, 10-5 M TPN is sufficiently stabilizing to permit storage of diluted G-6-PD (H) at 4°C for several days or to permit zero-order kinetics for several hours at 250C when assays of low activities of G-6-PD (H) are necessary. Adjustment of the hemolysates of H to 10-M in TPN in the purifications subsequently used resulted in a closer to normal percentage yield of G-6-PD.
To explore further the possible qualitative alterations in G-6-PD (H), the same cata-1.5_ A = 9. 5 X 103 CaL/MoLe lytic parameters were studied as previously were examined4' 12 in the G-6-PD from a normal, Caucasian, adult male (N) and from an asymptomatic negro adult male (S) with primaquine-sensitive erythrocytes, as mani- agents,19 age of the patient, or age of the erythrocytes, characterizations20 were made on the partially purified G-6-PD from the erythrocytes of another normal (N') and primaquine-sensitive adult (S') and from an infant (N") who had another type of hemolytic anemia associated with reticulocytosis comparable to (H) . All values agreed with the previously determined catalytic parameters (Figs. 2-4 ) for G-6-PD from a normal adult.
The preparations of G-6-PD from N and S have been found to use the abnormal substrate 2-deoxy-glucose-6-phosphate at a maximal rate only 9 per cent of that for G-6-P. Their Michaelis constant for 2-deoxy-glucose-6-phosphate is 6.9 X 10-4 M.12 Like the Michaelis constant for G-6-P, the constant for 2-deoxy-glucose-6-phosphate is some 4-5 times greater for H than for N. At concentrations of 6 X 10-4 molar the rate of utilization of 2-deoxy-glucose-6-phosphate compared to G-6-P was less with H than with N. This ratio more nearly approached the 9 per cent value when maximal velocities were estimated at infinite concentration of substrate.
DEAE column chromatography was performed on G-6-PD of N and H in the manner described elsewhere,4 except that the concentration of sodium phosphate buffer was maintained at 0.02 M throughout, and the linear gradient was obtained with increasing concentrations of sodium chloride. Prior to chromatography the enzymes were purified and dialyzed as described here, the 33-53 per cent ammonium sulfate fractionation being omitted to provide lactic dehydrogenase as a marker. A mixture of equal activities of N and H moved off of the column as a single peak in a pattern like that for N alone. Aliquots from both an early and a late portion of the peak from the mixed preparation had activities at pH 9.75 which were 60 per cent of those at pH 7.5, indicating that these aliquots were still mixtures of (Fig. 4) human erythrocytic G-6-PD and drawn. a deficiency of this activation in S cells, is particularly interesting. The findings here reported indicate that yet another genetic and molecular mechanism, involving qualitative changes,24 may operate to produce a deficiency in activity of human G-6-PD.
The anemia, or propensity for anemia, which seems to result from an impairment in erythrocytic G-6-PD, increases the likelihood that such persons will come under medical supervision and thereby facilitates selection of such mutants from the normal population. The existence of clinical variations6' 9, 13, 14 in mutants involving G-6-PD suggests that even further genotypes and molecular expressions, warranting investigation, may exist.
Summary.-Details are given of the discovery of two different enzymic expressions by genotypes which have been previously known to effect a deficiency in human erythrocytic glucose-6-phosphate dehydrogenase. One expression results in a qualitative alteration of the enzyme, a phenomenon which hitherto has been difficult to ascertain in higher forms of life.
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